Zenith Capital Corp
Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company's lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or meta… Read more
Zenith Capital Corp (ZHCLF) - Net Assets
Latest net assets as of July 2024: $-21.71K USD
Based on the latest financial reports, Zenith Capital Corp (ZHCLF) has net assets worth $-21.71K USD as of July 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.26K) and total liabilities ($29.97K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-21.71K |
| % of Total Assets | -262.7% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 95.01 |
Zenith Capital Corp - Net Assets Trend (2013–2024)
This chart illustrates how Zenith Capital Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zenith Capital Corp (2013–2024)
The table below shows the annual net assets of Zenith Capital Corp from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-04-30 | $-20.16K | -35.67% |
| 2023-04-30 | $-14.86K | -497.47% |
| 2022-04-30 | $-2.49K | -13.30% |
| 2021-04-30 | $-2.19K | +36.83% |
| 2020-04-30 | $-3.48K | +7.87% |
| 2019-04-30 | $-3.77K | -267.42% |
| 2018-04-30 | $2.25K | -77.41% |
| 2017-04-30 | $9.97K | +213.90% |
| 2016-04-30 | $-8.76K | -63.92% |
| 2015-04-30 | $-5.34K | -55.90% |
| 2014-04-30 | $-3.43K | +81.16% |
| 2013-04-30 | $-18.19K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zenith Capital Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10978700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $91.99K | % |
| Other Comprehensive Income | $4.30K | % |
| Other Components | $12.51K | % |
| Total Equity | $-20.16K | 100.00% |
Zenith Capital Corp Competitors by Market Cap
The table below lists competitors of Zenith Capital Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Macromill Embrain Co. Ltd
KQ:169330
|
$7.38 Million |
|
Induct AS
OL:INDCT
|
$7.38 Million |
|
Nuvotec
KQ:060260
|
$7.38 Million |
|
T T Limited
NSE:TTL
|
$7.38 Million |
|
Arrowhead Properties Ltd B
JSE:FTB
|
$7.38 Million |
|
Rokiskio Suris AB
MU:YTV
|
$7.38 Million |
|
INSIG AI PLC LS-01
F:8LF
|
$7.37 Million |
|
HYDROG.-REF.-SOL. EO-10
F:1FO
|
$7.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zenith Capital Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -14,859 to -20,159, a change of -5,300.
- Net loss of 10,596,000 reduced equity.
- Other comprehensive income increased equity by 2,160.
- Other factors increased equity by 10,588,540.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.60 Million | -52562.13% |
| Other Comprehensive Income | $2.16K | +10.71% |
| Other Changes | $10.59 Million | +52525.13% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Zenith Capital Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-04-30 | $0.00 | $0.05 | x |
| 2014-04-30 | $0.00 | $0.05 | x |
| 2015-04-30 | $0.00 | $0.05 | x |
| 2016-04-30 | $0.00 | $0.05 | x |
| 2017-04-30 | $0.00 | $0.05 | x |
| 2018-04-30 | $0.00 | $0.05 | x |
| 2019-04-30 | $0.00 | $0.05 | x |
| 2020-04-30 | $0.00 | $0.05 | x |
| 2021-04-30 | $0.00 | $0.05 | x |
| 2022-04-30 | $0.00 | $0.05 | x |
| 2023-04-30 | $0.00 | $0.05 | x |
| 2024-04-30 | $0.00 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zenith Capital Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-37402.24%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.62 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.16 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.92 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.18 Million |
| 2017 | -69554.75% | 0.00% | 0.00x | 1.31x | $-6.94 Million |
| 2018 | -379272.08% | 0.00% | 0.00x | 1.75x | $-8.55 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.95K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.55K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.87K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.41K |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.12 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.59 Million |
Industry Comparison
This section compares Zenith Capital Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zenith Capital Corp (ZHCLF) | $-21.71K | 0.00% | N/A | $7.38 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |